TITLE

New antihistamine gets FDA green light

AUTHOR(S)
Belden, Heidi
PUB. DATE
July 2007
SOURCE
Drug Topics;7/9/2007, Vol. 151 Issue 13, p13
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports that Levocetizine from UCB Inc. and Sanofi-Aventis has received regulatory approval from the U.S. Food & Drug Administration for the relief of the symptoms of seasonal and perennial allergic rhinitis. Levocetirizine is also for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in the same age group. The manufacturer said that peak plasma concentrations of levocetirizine are achieved 0.9 hours after dosing, with activity persisting for at least 24 hours.
ACCESSION #
25886313

 

Related Articles

  • New hay fever, hives treatment approved. Young, Donna // American Journal of Health-System Pharmacy;7/1/2007, Vol. 64 Issue 13, p1352 

    The article reports on the move of the Food and Drug Administration to grant a marketing approval for levocetirizine dihydrochloride or Xyzal on May 29, 2007 in the U.S. The drug, which is manufactured by UCB Chemical Corp. and Sanofi-Aventis SA, is an oral antihistamine used for treatment of...

  • ALLERGIC DISORDERS.  // MPR - Pharmacist's Edition;Summer2012, Vol. 6 Issue 2, p1 

    The article offers information on the drug literature for allergic disorders. It mentions Wyeth Consumer Healthcare Inc.'s Alavert, an antihistamine, which is indicated for seasonal allergic rhinitis. It notes Sanofi Aventis SA's Allegra which is used for the treatment of chronic idiopathic...

  • REVISED.  // Monthly Prescribing Reference;Jan2013, Vol. 29 Issue 1, p1 

    The article offers information on various drugs used for the treatment of allergic disorders. It mentions that one of the drugs Allegra from Sanofi-Aventis SA is used for the treatment of chronic idiopathic urticaria. It informs that another drug Clarinex from Merck & Co. Inc. is used for...

  • New approval for head and neck cancer.  // Drug Topics;11/6/2006, Vol. 150 Issue 21, p6 

    The article reports that U.S. Food and Drug Administration has granted Sanofi-Aventis SA a regulatory approval to market docetaxel, brand name Taxotere, Injection Concentrate to be used in combination with cisplatin and fluorouracil for the induction treatment of patients suffering with...

  • Nasal spray approved for kids ages 2 to 5.  // Contemporary Pediatrics;Oct2008, Vol. 25 Issue 10, p19 

    The article announces that the U.S. Food & Drug Administration (FDA) has approved the Nasacort AQ nasal spray, manufactured by sanofi-aventis, for sneezing, runny nose, and congestion caused by allergic rhinitis in pre-schoolers. It was tested in a randomized, double-blind, placebo-controlled...

  • Sanofi-aventis Gets OK. to Sell Allegra as O-T-C.  // MMR;2/21/2011, Vol. 28 Issue 4, p24 

    The article reports that the allergy medication Allegra from Sanofi-aventis SA has been approved for over-the-counter sale by the U.S. Food and Drug Administration.

  • FDA: MedImmune's Rezield has 3x Allergic Reactions as Synagis. Young, Donna // BioWorld Today;6/1/2010, Vol. 21 Issue 104, p1 

    The article offers a look on the findings of the U.S. Food and Drug Administration (FDA) about the investigational respiratory syncytial virus (RSV) drug Rezield of MedImmune Inc. The agency revealed that the drug had three times as many nonfatal adverse hypersensitivity events, including...

  • SECTION 8: ALLERGIC DISORDERS.  // MPR - Urologists' Edition;Fall2011/Winter2012, Vol. 8 Issue 2, p88 

    The article offers information on various drugs used for the treatment of allergic disorders. One of these drugs is Allegra manufactured by Sanofi-Aventis SA for the treatment of allergic rhinitis (seasonal) and chronic idiopathic urticaria. Another is Benadryl Allergy from McNeil Cons &...

  • CONSUMER MARKETING: Update.  // Medical Marketing & Media;Oct2009, Vol. 44 Issue 10, p27 

    The article offers news briefs related to the pharmaceutical industry in the U.S. UCB Inc. and Sanofi-Aventis SA has refreshed their My Xperts program. The Pharmaceutical Research & Manufacturers of America (PhRMA) said a proposed FDA study of benefit information in direct-to-consumer (DTC)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics